COMPASS Pathways plc CMPS
9.01 USD -0.17 (-1.91%)
Nov 10, 2026, 11:29 AM EST
8.95 Day range 9.49
4.88 52-week range 15.87
- YTD
- +30.51%
- 1 year
- +56.88%
News
benzinga.com Compass Pathways Submits FDA New Drug Application For Comp360 Psilocybin For Treatment-Resistant Depression Robust NDA submission supported by data from two highly statistically significant Phase 3 trials and a Phase 2b study that each met its primary endpoint and involved a total of more than 1,000…
benzinga.com HC Wainwright & Co. Reiterates Buy on Compass Pathways, Maintains $65 Price Target HC Wainwright & Co. analyst Patrick R. Trucchio reiterates Compass Pathways (NASDAQ:CMPS) with a Buy and maintains $65 price target.
defenseworld.net Compass Pathways Q3 Earnings Call Highlights Compass Pathways (NASDAQ: CMPS) said it expects to complete its rolling New Drug Application submission for COMP360, its investigational psilocybin treatment for treatment-resistant depression,…
benzinga.com Wells Fargo Maintains Equal-Weight on Compass Pathways, Lowers Price Target to $10 Wells Fargo analyst Benjamin Burnett maintains Compass Pathways (NASDAQ:CMPS) with a Equal-Weight and lowers the price target from $13 to $10.
businesswire.com Compass Pathways to Participate in Stifel 2026 Healthcare Conference on November 11th LONDON & JERSEY CITY, N.J.--(BUSINESS WIRE)---- $CMPS #Biotech--Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to unlocking urgently needed new treatment options in mental…
fool.com Compass Pathways: 3 Key Takeaways for Long-Term Investors COMPASS will complete its New Drug Application submission within two weeks. Interventional psychiatrists surveyed show 90% willingness to prescribe COMP360.
seekingalpha.com COMPASS Pathways plc (CMPS) Q3 2026 Earnings Call Transcript COMPASS Pathways plc (CMPS) Q3 2026 Earnings Call Transcript
marketbeat.com Compass Pathways Q3 Earnings Call Highlights Compass Pathways NASDAQ: CMPS said it expects to complete its rolling New Drug Application submission for COMP360, its investigational psilocybin treatment for treatment-resistant depression, within…
benzinga.com 12 Health Care Stocks Moving In Tuesday's Pre-Market Session Gainers Dyadic International (NASDAQ:DYAI) stock rose 13.4% to $0.43 during Tuesday's pre-market session. The market value of their outstanding shares is at $15.0 million. Aethlon Medical…
benzinga.com Compass Pathways Q3 EPS $(0.31) Beats $(0.43) Estimate Compass Pathways (NASDAQ:CMPS) reported quarterly losses of $(0.31) per share which beat the analyst consensus estimate of $(0.43) by 27.91 percent. This is a 18.42 percent increase over losses of…
businesswire.com Compass Pathways Announces Third Quarter 2026 Financial Results and Business Highlights LONDON & JERSEY CITY, N.J.--(BUSINESS WIRE)---- $CMPS #Biotech--Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to unlocking urgently needed new treatment options in mental…- benzinga.com Compass Pathways Issues New Report Summarizing Findings From National Survey Of People Living With TRD And Caregivers On The Burden Of Prolonged Depressive Episodes Without Meaningful Relief The survey findings demonstrate the impact of TRD across various aspects of everyday life, with many patients reporting years spent cycling through treatments without significant improvement while…
benzinga.com Compass Pathways Reports Q2 2026 Results: Full Earnings Call Transcript Compass Pathways (NASDAQ:CMPS) released second-quarter financial results and hosted an earnings call on Wednesday. Read the complete transcript below. This content is powered by Benzinga APIs. For…- benzinga.com Compass Pathways Announces U.S. Healthcare Provider Grant Program Recipients To Create Training For Delivery Of Psychedelic Treatments These programs are intended to address both the need for foundational training in psychedelics, as well as ensuring HCPs are well-prepared to care for patients receiving treatment with COMP360…
benzinga.com Compass Pathways’ Psilocybin Treatment Shows Lasting Benefits in Treatment-Resistant Depression Compass Pathways surges 11% after COMP360 Phase 3 trial shows durable 52-week relief for treatment-resistant depression.- benzinga.com Compass Pathways Shares Topline 52-week Results (Part C) From Its Phase 3 COMP005 Trial Of Comp360 For Treatment-Resistant Depression, Showing Additional Benefit Extending Durability Out To 1 Year Notable additional benefit observed with an added reduction in MADRS1 score leading to an average 13-point reduction from baseline at Week 52 with durability extended out to 1 year for participants…
benzinga.com 'FDA’s Acting Drug, Vaccine Regulators Tapped for Permanent Roles'- Bloomberg https://www.bloomberg.com/news/articles/2026-09-08/fda-s-acting-drug-vaccine-regulators-tapped-for-permanent-roles- benzinga.com Compass Pathways To Participate In Psych Congress 2026 With New Educational Campaign Regarding Treatment-Resistant Depression Congress taking place in New Orleans, LA, from September 14-19. The Company will debut Change the Tune in TRD, a new educational campaign for U.S. HCPs focused on TRD, and present new HEOR data…
benzinga.com 10 Health Care Stocks With Whale Alerts In Today’s Session This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity…
benzinga.com HC Wainwright & Co. Maintains Buy on Compass Pathways, Lowers Price Target to $65 HC Wainwright & Co. analyst Patrick R. Trucchio maintains Compass Pathways (NASDAQ:CMPS) with a Buy and lowers the price target from $70 to $65.- benzinga.com Morgan Stanley Maintains Overweight on Compass Pathways, Raises Price Target to $18 Morgan Stanley analyst Judah Frommer maintains Compass Pathways (NASDAQ:CMPS) with a Overweight and raises the price target from $17 to $18.
- benzinga.com RBC Capital Maintains Outperform on Compass Pathways, Lowers Price Target to $21 RBC Capital analyst Leonid Timashev maintains Compass Pathways (NASDAQ:CMPS) with a Outperform and lowers the price target from $22 to $21.
- benzinga.com B. Riley Securities Maintains Buy on Compass Pathways, Raises Price Target to $22 B. Riley Securities analyst Madison El-Saadi maintains Compass Pathways (NASDAQ:CMPS) with a Buy and raises the price target from $17 to $22.
- benzinga.com Compass Pathways Collaborates With U.S. Department Of Veterans Affairs On A Multi-Site Randomized Controlled Clinical Trial The study will evaluate the safety and efficacy of COMP360 psilocybin in the treatment of treatment-resistant depression (TRD) in veterans, including those with concurrent post-traumatic stress…
- benzinga.com UPDATE: Compass Pathways Q2 Adj. EPS $(0.36) Beats $(0.40) Estimate. (Adj EPS excludes Fair value change of warrant liabilities) Compass Pathways (NASDAQ:CMPS) reported quarterly losses of $(0.36) per share which beat the analyst consensus estimate of $(0.40) by 10 percent. This is a 12.2 percent increase over losses of…
- benzinga.com Compass Pathways Q2 EPS $(1.88) Misses $(0.37) Estimate Compass Pathways (NASDAQ:CMPS) reported quarterly losses of $(1.88) per share which missed the analyst consensus estimate of $(0.37) by 408.11 percent. This is a 358.54 percent decrease over losses…
- benzinga.com Wells Fargo Initiates Coverage On Compass Pathways with Equal-Weight Rating, Announces Price Target of $13 Wells Fargo analyst Benjamin Burnett initiates coverage on Compass Pathways (NASDAQ:CMPS) with a Equal-Weight rating and announces Price Target of $13.
benzinga.com Why Is Robinhood Stock Falling on Thursday? Robinhood Markets Inc. (NASDAQ: HOOD) stock declines on Thursday due to tech market pullbacks, recent ARK Invest portfolio shifts and upcoming Q2 earnings.
benzinga.com Cathie Wood Swaps Robinhood for SpaceX, Archer—Did ARK Pivot Back to Moonshot Innovation? Cathie Wood sold $10M of Robinhood while adding $15M to SpaceX and boosting Archer Aviation. Here's what ARK Invest's ETF rotation signals.
benzinga.com Why Is Neuronetics Stock Soaring Monday? BTIG initiates coverage on Neuronetics (STIM) with a Buy rating and $5 target as shares surge 28%. Read the details here.
benzinga.com Why Is GH Research Stock Trading Higher on Thursday? GH Research and Definium Therapeutics stocks rose after Eli Lilly agreed to buy AtaiBeckley in a deal worth up to $3.8 billion.
benzinga.com Compass Pathways Announces Publication Of Post-Hoc Analysis Of Support Methods In Phase 2 Study Of Investigational COMP360 Synthetic Psilocybin Treatment Post-hoc analysis of support methods used in an open-label Phase 2 COMP360 study showed monitoring and support provided during treatment administration sessions were minimal, non-directive and…
benzinga.com Why JB Hunt Shares Are Trading Higher By Around 8%; Here Are 20 Stocks Moving Premarket JB Hunt Transport Services Inc (JBHT) beat earnings and revenue estimates, causing shares to surge 7.9% in pre-market trading. Other top gainers include ATPC, TGHL, ATAI, DXST, KAPA, EHGO, HELP, VSA,…- benzinga.com 6 Health Care Stocks With Whale Alerts In Today’s Session This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity…
- benzinga.com HC Wainwright & Co. Reiterates Buy on Compass Pathways, Maintains $70 Price Target HC Wainwright & Co. analyst Patrick R. Trucchio reiterates Compass Pathways (NASDAQ:CMPS) with a Buy and maintains $70 price target.
- benzinga.com Evercore ISI Group Upgrades Compass Pathways to Outperform, Raises Price Target to $21 Evercore ISI Group analyst Gavin Clark-Gartner upgrades Compass Pathways (NASDAQ:CMPS) from In-Line to Outperform and raises the price target from $8 to $21.
- benzinga.com Stifel Maintains Buy on Compass Pathways, Raises Price Target to $21 Stifel analyst Paul Matteis maintains Compass Pathways (NASDAQ:CMPS) with a Buy and raises the price target from $14 to $21.
- benzinga.com Morgan Stanley Reiterates Overweight on Compass Pathways, Maintains $17 Price Target Morgan Stanley analyst Judah Frommer reiterates Compass Pathways (NASDAQ:CMPS) with a Overweight and maintains $17 price target.
- benzinga.com Oppenheimer Reiterates Outperform on Compass Pathways, Maintains $20 Price Target Oppenheimer analyst Francois Brisebois reiterates Compass Pathways (NASDAQ:CMPS) with a Outperform and maintains $20 price target.
- benzinga.com BTIG Maintains Buy on Compass Pathways, Raises Price Target to $25 BTIG analyst Thomas Shrader maintains Compass Pathways (NASDAQ:CMPS) with a Buy and raises the price target from $14 to $25.
benzinga.com Compass Pathways Highlights Long-Term Data from Resistant Depression, Backs 2027 Launch Timeline Compass Pathways reported positive 26-week Phase 3 COMP360 data for treatment-resistant depression as its FDA filing remains on track.- benzinga.com Compass Pathways Announces 26-Week Results From Second Ongoing Phase 3 COMP006 Trial Of COMP360, Proprietary Formulation Of Psilocybin, For TRD Which Confirm COMP360’s Rapid Onset And Durable Profile New 6-month data supports COMP360’s potential to establish a new standard of care in TRDData from positive COMP006 Phase 3 trial demonstrates durable benefit through at least 6 months further…
benzinga.com Canaccord Genuity Maintains Buy on Compass Pathways, Raises Price Target to $20 Canaccord Genuity analyst Sumant Kulkarni maintains Compass Pathways (NASDAQ:CMPS) with a Buy and raises the price target from $18 to $20.
benzinga.com Why LiveRamp Shares Are Trading Higher By Over 26%; Here Are 20 Stocks Moving Premarket Liveramp Holdings Inc (NYSE: RAMP) rose in pre-market trading after being acquired by Publicis for $2.2 billion. Other gainers include SBFM, NXXT, GOVX, CREG, PMI, ZDAI, GCTS, CMPS, and DXYZ. BTM,…- benzinga.com Maxim Group Maintains Buy on Compass Pathways, Raises Price Target to $20 Maxim Group analyst Jason McCarthy maintains Compass Pathways (NASDAQ:CMPS) with a Buy and raises the price target from $12 to $20.
- benzinga.com Morgan Stanley Maintains Overweight on Compass Pathways, Raises Price Target to $17 Morgan Stanley analyst Judah Frommer maintains Compass Pathways (NASDAQ:CMPS) with a Overweight and raises the price target from $16 to $17.
- benzinga.com RBC Capital Maintains Outperform on Compass Pathways, Raises Price Target to $22 RBC Capital analyst Leonid Timashev maintains Compass Pathways (NASDAQ:CMPS) with a Outperform and raises the price target from $21 to $22.
- benzinga.com Transcript: Compass Pathways Q1 2026 Earnings Conference Call
benzinga.com Compass Pathways Reports Strong Q1 Results, Shares Surge COMPASS Pathways Plc (NASDAQ:CMPS) reported first-quarter earnings on Wednesday before the market open. Here's a rundown of the report.
benzinga.com Earnings Scheduled For May 13, 2026